Neoadjuvant SHR-1701 Plus Famitinib With Response-guided Adjuvant Therapy in Resectable Mucosal Melanoma

Sponsor
Shanghai Zhongshan Hospital
Study ID
NCT07517653
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • SHR-1701 — DRUG
    Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China
  • Famitinib — DRUG
    Specifically targets mucosal melanoma, which accounts for 22.6% of melanoma cases in China

Study Details

This study aims to investigate the efficacy and safety of SHR-1701 in combination with famitinib in the perioperative treatment of mucosal melanoma

Key Dates

First listed
Apr 8, 2026
Start date
Apr 1, 2026
Status verified
Mar 2026
Primary completion
Nov 30, 2028
Completion
Dec 30, 2028

Study Design

Enrollment
70 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: SHR-1701 + Famitinib

Primary Outcome Measure

Event-Free Survival, EFS [ Time Frame: From start of treatment to end of study, up to approximately 36 months ]

Find similar trials

Nationwide
Melanoma trialsOncology trialsSkin cancer trialsDermatology trials

Related Studies